Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 4
1999 1
2000 1
2011 2
2012 2
2013 1
2015 1
2017 2
2021 1
2022 2
2023 1
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
Mekinian A, Zhao LP, Chevret S, Desseaux K, Pascal L, Comont T, Maria A, Peterlin P, Terriou L, D'Aveni Piney M, Gourin MP, Vey N, Rauzy OB, Grobost V, Bezanahary H, Dimicoli-Salazar S, Banos A, Wickenhauser S, De Renzis B, Durot E, Natarajan-Amé S, Voillat L, Chermat F, Lemaire K, Jachiet V, Himberlin C, Thépot S, Diaz JMT, Frenzel L, Gyan E, Denis G, Hirsch P, Kosmider O, Ades L, Fain O, Fenaux P. Mekinian A, et al. Among authors: rauzy ob. Leukemia. 2022 Nov;36(11):2739-2742. doi: 10.1038/s41375-022-01698-8. Epub 2022 Sep 14. Leukemia. 2022. PMID: 36104395 Clinical Trial. No abstract available.
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).
Cluzeau T, Sebert M, Rahmé R, Cuzzubbo S, Lehmann-Che J, Madelaine I, Peterlin P, Bève B, Attalah H, Chermat F, Miekoutima E, Rauzy OB, Recher C, Stamatoullas A, Willems L, Raffoux E, Berthon C, Quesnel B, Loschi M, Carpentier AF, Sallman DA, Komrokji R, Walter-Petrich A, Chevret S, Ades L, Fenaux P. Cluzeau T, et al. Among authors: rauzy ob. J Clin Oncol. 2021 May 10;39(14):1575-1583. doi: 10.1200/JCO.20.02342. Epub 2021 Feb 18. J Clin Oncol. 2021. PMID: 33600210 Free PMC article. Clinical Trial.
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry.
de Valence B, Delaune M, Nguyen Y, Jachiet V, Heiblig M, Jean A, Riescher Tuczkiewicz S, Henneton P, Guilpain P, Schleinitz N, Le Guenno G, Lobbes H, Lacombe V, Ardois S, Lazaro E, Langlois V, Outh R, Vinit J, Martellosio JP, Decker P, Moulinet T, Dieudonné Y, Bigot A, Terriou L, Vlakos A, de Maleprade B, Denis G, Broner J, Kostine M, Humbert S, Lifermann F, Samson M, Pechuzal S, Aouba A, Kosmider O, Dion J, Grosleron S, Bourguiba R, Terrier B, Georgin-Lavialle S, Fain O, Mekinian A, Morgand M, Comont T, Hadjadj J; French VEXAS Group. de Valence B, et al. Ann Rheum Dis. 2024 Feb 15;83(3):372-381. doi: 10.1136/ard-2023-224819. Ann Rheum Dis. 2024. PMID: 38071510
Nutritional support and aging in preoperative nutrition.
Nourhashemi F, Andrieu S, Rauzy O, Ghisolfi A, Vellas B, Chumlea WC, Albarede JL. Nourhashemi F, et al. Among authors: rauzy o. Curr Opin Clin Nutr Metab Care. 1999 Jan;2(1):87-92. doi: 10.1097/00075197-199901000-00015. Curr Opin Clin Nutr Metab Care. 1999. PMID: 10453336 Review.
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, Hou HA, Kwong YL, Arnan M, Meers S, Pullarkat V, Santini V, Malek K, Kiertsman F, Niolat J, Ramos PM, Menssen HD, Fenaux P, Miyazaki Y, Platzbecker U. Zeidan AM, et al. Among authors: rauzy o. Lancet Haematol. 2024 Jan;11(1):e38-e50. doi: 10.1016/S2352-3026(23)00333-2. Epub 2023 Dec 5. Lancet Haematol. 2024. PMID: 38065203 Clinical Trial.
[Messages from the estates general on French internal medicine].
Sève P, Morlat P, Ranque B, Lavigne C, Bourgarit A, Rauzy O, Godeau B, Mouthon L. Sève P, et al. Among authors: rauzy o. Rev Med Interne. 2024 Feb;45(2):69-78. doi: 10.1016/j.revmed.2024.01.010. Epub 2024 Jan 30. Rev Med Interne. 2024. PMID: 38290857 French.
Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms.
Dussiau C, Comont T, Knosp C, Vergnolle I, Bravetti C, Canali A, Houvert A, Largeaud L, Daveaux C, Zaroili L, Friedrich C, Boussaid I, Zalmai L, Almire C, Rauzy O, Willems L, Birsen R, Bouscary D, Fontenay M, Kosmider O, Chapuis N, Vergez F. Dussiau C, et al. Among authors: rauzy o. Leukemia. 2024 May;38(5):1131-1142. doi: 10.1038/s41375-024-02234-6. Epub 2024 Apr 4. Leukemia. 2024. PMID: 38575672 Free PMC article.
Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia.
Walter O, Ribes A, Germain J, Rieu JB, Comont T, Plat A, Rivière B, Deluche L, Delarue L, LeGoff I, Greze M, Dubourdieu B, Rauzy O, Mansat-De Mas V, Moulis G; CARMEN investigators group.. Walter O, et al. Among authors: rauzy o. Platelets. 2022 Nov 17;33(8):1153-1158. doi: 10.1080/09537104.2022.2053089. Epub 2022 Mar 29. Platelets. 2022. PMID: 35348426
22 results